Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
50
20
22
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
10.0%
5 terminated/withdrawn out of 50 trials
58.3%
-28.2% vs industry average
12%
6 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (50)
A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.
Role: lead
Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
Role: lead
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Role: lead
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Role: lead
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Role: lead
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
Role: lead
Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis
Role: lead
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Role: lead
Treatment of Moderate to Severe Plaque Psoriasis
Role: lead
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
Role: lead
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Role: lead
Clinical Studies for the Treatment of Advanced Solid Tumors
Role: lead
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
Role: lead
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Role: lead
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Role: lead
A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
Role: lead
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Role: lead
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Role: lead
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
Role: lead
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
Role: lead